Open access · CC-BY
via OpenAlex
Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor
Jilly F. Evans, Ryan W. Rue, Alexander R. Mukhitov, Kseniya Obraztsova, Carly J. Smith, Vera P. Krymskaya
Biomolecules · 2019 · ▲ 8 citations
Abstract
Lymphangioleiomyomatosis (LAM) is a rare metastatic cystic lung disease due to a mutation in a TSC tumor suppressor, resulting in hyperactive mTOR(definition) growth pathways. Sirolimus (rapamycin(definition)), an allosteric mTORC1 inhibitor, is a therapeutic option for women with LAM but it only maintains lung volume during treatment and does not provide benefit for all LAM patients. The two major mTORC1 protein synthesis pathways are via S6K/S6 or 4E-BP/eIF4E activation. We aimed to investigate rapamycin in combination with compounds that target associated growth pathways, with the potential to be additive to rapamycin. In this study we demonstrated that rapamycin, at a clinically tolerable concentration (10 nM), inhibited the phosphorylation of S6, but not the critical eIF4E releasing Thr 37/46 phosphorylation sites of 4E-BP1 in TSC2-deficient LAM-derived cells. We also characterized the abundant protein expression of peIF4E within LAM lesions. A selective MNK1/2 inhibitor eFT508 inhibited the phosphorylation of eIF4E but did not reduce TSC2-null cell growth. In contrast, a PI3K/mTOR inhibitor omipalisib blocked the phosphorylation of Akt and both S6K/S6 and 4E-BP/eIF4E branches, and additively decreased the growth of TSC2-null cells with rapamycin. Omipalisib, or another inhibitor of both major mTORC1 growth pathways and pAkt, might provide therapeutic options for TSC2-deficient cancers including, but not limited to, LAM.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3390/biom10010028
- Canonical
- link ↗
- Fetched
- 2026-10-29 MST
Cite this
APA
Evans, J.F., Rue, R.W., Mukhitov, A.R., Obraztsova, K., Smith, C.J., & Krymskaya, V.P. (2019). Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor. <em>Biomolecules</em>. https://doi.org/10.3390/biom10010028
Vancouver
Evans JF, Rue RW, Mukhitov AR, Obraztsova K, Smith CJ, Krymskaya VP. Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor. Biomolecules. 2019. doi:10.3390/biom10010028.
BibTeX
@article{jilly2019Inhibi,
title = {Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor},
author = {Jilly F. Evans and Ryan W. Rue and Alexander R. Mukhitov and Kseniya Obraztsova and Carly J. Smith and Vera P. Krymskaya},
journal = {Biomolecules},
year = {2019},
doi = {10.3390/biom10010028},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Cell Cycle 2011
Open access · OA
High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1
Cancer Biology & Therapy 2013
Open access · OA
Dysregulation of the mTOR pathway in p53-deficient mice
Research and Reports in Biology 2015
Open access · CC-BY
Recent insights into the pathophysiology of mTOR pathway dysregulation
Aging 2016
Open access · CC-BY
Gerosuppression by pan-mTOR inhibitors
Aging 2011
Open access · CC-BY
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
PLoS ONE 2013
Open access · CC-BY